Your browser doesn't support javascript.
loading
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan, Lale; van den Bent, Martin J; Hoogstrate, Youri; Naz-Khan, Hina; Stubbs, Andrew; van der Spek, Peter; Böttcher, René; Gao, Ya; de Wit, Maurice; Taal, Walter; Oosterkamp, Hendrika M; Walenkamp, Annemiek; Beerepoot, Laurens V; Hanse, Monique C J; Buter, Jan; Honkoop, Aafke H; van der Holt, Bronno; Vernhout, René M; Sillevis Smitt, Peter A E; Kros, Johan M; French, Pim J.
Afiliação
  • Erdem-Eraslan L; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • van den Bent MJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Hoogstrate Y; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Bioinformatics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Naz-Khan H; Bioinformatics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Stubbs A; Bioinformatics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • van der Spek P; Bioinformatics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Böttcher R; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Gao Y; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • de Wit M; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Taal W; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Oosterkamp HM; Department of Medical Oncology, Medical Center Haaglanden, The Hague, the Netherlands.
  • Walenkamp A; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
  • Beerepoot LV; Department of Oncology, St Elisabeth Ziekenhuis, Tilburg, the Netherlands.
  • Hanse MC; Department of Neurology, Catharina Hospital Eindhoven, the Netherlands.
  • Buter J; Department of Oncology, VU University Medical Center, Amsterdam, the Netherlands.
  • Honkoop AH; Department of Internal Medicine, Isala Kliniek, Zwolle, the Netherlands.
  • van der Holt B; Clinical Trial Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Vernhout RM; Clinical Trial Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Sillevis Smitt PA; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Kros JM; Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • French PJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. p.french@erasmusmc.nl.
Cancer Res ; 76(3): 525-34, 2016 Feb 01.
Article em En | MEDLINE | ID: mdl-26762204
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda